IL137937A0 - A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal - Google Patents

A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

Info

Publication number
IL137937A0
IL137937A0 IL13793700A IL13793700A IL137937A0 IL 137937 A0 IL137937 A0 IL 137937A0 IL 13793700 A IL13793700 A IL 13793700A IL 13793700 A IL13793700 A IL 13793700A IL 137937 A0 IL137937 A0 IL 137937A0
Authority
IL
Israel
Prior art keywords
mammal
prevention
treatment
pharmaceutical composition
nicotine addiction
Prior art date
Application number
IL13793700A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL137937A0 publication Critical patent/IL137937A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13793700A 1999-08-27 2000-08-17 A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal IL137937A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15108999P 1999-08-27 1999-08-27

Publications (1)

Publication Number Publication Date
IL137937A0 true IL137937A0 (en) 2001-10-31

Family

ID=22537272

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13793700A IL137937A0 (en) 1999-08-27 2000-08-17 A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

Country Status (10)

Country Link
US (1) US20030109544A1 (ja)
EP (1) EP1078637A3 (ja)
JP (1) JP2001072604A (ja)
KR (1) KR20010050225A (ja)
AU (2) AU775095B2 (ja)
CA (1) CA2317064A1 (ja)
HU (1) HUP0003410A3 (ja)
IL (1) IL137937A0 (ja)
PE (1) PE20010577A1 (ja)
ZA (1) ZA200004406B (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA003190B1 (ru) 1997-12-31 2003-02-27 Пфайзер Продактс Инк. Азаполициклические соединения, конденсированные с арилом
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
US20080138398A1 (en) * 1999-07-16 2008-06-12 Aradigm Corporation Dual release nicotine formulations, and systems and methods for their use
US8256433B2 (en) * 1999-07-16 2012-09-04 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
US20080138294A1 (en) * 1999-07-16 2008-06-12 Igor Gonda Systems and methods for effecting cessation of tobacco use
US20080138399A1 (en) * 1999-07-16 2008-06-12 Aradigm Corporation Dual release nicotine formulations, and systems and methods for their use
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
DE10018834A1 (de) * 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
DK1383733T3 (da) * 2001-04-20 2008-06-09 Pfizer Prod Inc Fremgangsmåde til fremstilling af 1,3-substituerede indener og aryl-sammenföjede azapolycykliske forbindelser
JP3779682B2 (ja) * 2001-05-14 2006-05-31 ファイザー・プロダクツ・インク ５，８，１４−トリアザテトラシクロ［１０．３．１．０２，１１．０４，９］−ヘキサデカ−２（１１），３，５，７，９−ペンタンの酒石酸塩及びその医薬組成物
DOP2002000390A (es) * 2001-05-14 2003-03-15 Pfizer Prod Inc Sal citrato de 5,8 14-hiezatetraciclo [10.3.1.0 2,11. 0.4.9] hexadeca-2(11),3,5,8,9, pentaeno y composiciones farmaceuticas de las mismas
US20040037879A1 (en) * 2001-11-02 2004-02-26 Adusumilli Prasad S. Oral controlled release forms useful for reducing or preventing nicotine cravings
WO2005000806A2 (en) 2003-06-10 2005-01-06 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20090318491A1 (en) * 2006-01-27 2009-12-24 Yale Univeristy Cytisine and Acetylcholine Analogs and Methods of Treating Mood Disorders
CN101855218A (zh) 2007-09-13 2010-10-06 康塞特医药品有限公司 氘化的儿茶酚和苯并[d][1,3]间二氧杂环戊烯及其衍生物的合成
US20110182831A1 (en) * 2010-01-25 2011-07-28 Aradigm Corporation Systems and methods used in conjunction with nicotine vaccines for effecting cessation of tobacco use
CN111432817B (zh) 2017-11-29 2023-10-31 凡德贝尔大学 抑制肿瘤移转的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235734B1 (en) * 1996-10-30 2001-05-22 Pfizer Inc Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
WO1999017803A1 (en) * 1997-10-03 1999-04-15 Cary Medical Corporation Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug
KR20010031470A (ko) * 1997-10-28 2001-04-16 둘락 노먼 씨. 포유동물의 갈망을 감소시키는 방법
EA003190B1 (ru) * 1997-12-31 2003-02-27 Пфайзер Продактс Инк. Азаполициклические соединения, конденсированные с арилом
SE9803732D0 (sv) * 1998-11-02 1998-11-02 Maria Carlsson Nicotine treatment for obsessive compulsive disorder
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique

Also Published As

Publication number Publication date
HUP0003410A3 (en) 2001-09-28
CA2317064A1 (en) 2001-02-27
HUP0003410A2 (hu) 2001-05-28
ZA200004406B (en) 2002-02-25
PE20010577A1 (es) 2001-05-08
AU775095B2 (en) 2004-07-15
EP1078637A2 (en) 2001-02-28
HU0003410D0 (en) 2000-08-25
KR20010050225A (ko) 2001-06-15
AU2004220766A1 (en) 2004-11-11
AU5351600A (en) 2001-03-08
US20030109544A1 (en) 2003-06-12
JP2001072604A (ja) 2001-03-21
EP1078637A3 (en) 2003-03-05

Similar Documents

Publication Publication Date Title
IL137937A0 (en) A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
HUP0204023A3 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders and pharmaceutical compositions containing them
HK1040995A1 (zh) 二氧喹啉化合物及其醫藥用途
HK1054029A1 (en) 4-aminopiperidine derivatives and their use as medicine
HUP0203588A3 (en) Analgesic pharmaceutical compositions and their use
IL149618A0 (en) Pharmaceutical compositions comprising thiazolidinedione and process for preparation thereof
HUP0301325A3 (en) Stabilized pharmaceutically effective composition and pharmaceutical composition comprising the same and process for preparation the composition
HUP0200548A2 (hu) Gyógyszerészeti készítmények és alkalmazásuk
HU0103078D0 (en) Pharmaceutical compositions and methods for treating cataracts
HK1035146A1 (en) Pharmaceutical composition for use in emergency treatment and preparation method thereof
HUP0300848A3 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
PL363048A1 (en) Azabicyclic derivatives and their therapeutic use
HUP0402326A3 (en) Pharmaceutical composition for prevention of addiction in pain management
AU1917602A (en) Dihydroindole and tetrahydroquinoline derivatives
PL354412A1 (en) L-acetylcarnitine and l-propionylcarnitine containing composition for the prevention and treatment of kidney dysfunctions and diseases
HK1047217A1 (zh) 烟具
HUP0203383A3 (en) Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof
HUP0201478A3 (en) Neuroprotective and retinoprotective ophthalmologic medicines
IL152827A0 (en) Herbal composition useful for treatment of oral cavity and a method for the local delivery thereof
HUP9902725A2 (hu) Ciprofloxacintartalmú gyógyászati készítmény és eljárás annak előállítására
PL345781A1 (en) Utilization of derivatives of tetrahydropyridines (or 4-hydroxypiperidines)-butylazols in the preparation of a medicament for the treatment of pain
GB0007788D0 (en) Method to evaluate the therapeutic and toxic effects related to drug administration
EP1243275A4 (en) INSULIN-CONTAINING MEDICINE FOR PERSONAL USE AND METHOD FOR THEIR PRODUCTION
GB9930342D0 (en) Improved composition and method for the treatment of drug abuse
GB9915539D0 (en) Composition and method for the treatment of drug abuse